The oral GSK3-α/β and CDK9 inhibitor, ABC1183, led to a dramatic improvement in dextran sulfate sodium- and 2,4,6-trinitrobenzene sulfonic acid- induced colitis that was associated with suppression of TNF-α and IL-6, and no observed organ or hematological toxicity.41 This evidence concerns the gene GSK3A and colitis.